PT  - JOURNAL ARTICLE
AU  - ISHIKAWA, TORU
AU  - SATO, RYO
AU  - JIMBO, RYO
AU  - KOBAYASHI, YUJI
AU  - SATO, TOSHIFUMI
AU  - IWANAGA, AKITO
AU  - SANO, TOMOE
AU  - YOKOYAMA, JUNJI
AU  - HONMA, TERASU
TI  - Determinants of Survival of Ablation Treatment for Portal Vein Tumor Thrombus in Patients With Hepatocellular Carcinoma
AID  - 10.21873/invivo.13721
DP  - 2024 Sep 01
TA  - In Vivo
PG  - 2501--2505
VI  - 38
IP  - 5
4099  - http://iv.iiarjournals.org/content/38/5/2501.short
4100  - http://iv.iiarjournals.org/content/38/5/2501.full
SO  - In Vivo2024 Sep 01; 38
AB  - Background/Aim: The prognosis of hepatocellular carcinoma (HCC) complicated with portal vein tumor thrombus (PVTT) is extremely poor. This study investigated whether local ablation—a curative treatment similar to resection—could improve the prognosis of patients with Child-Pugh B/C PVTT. Patients and Methods: Between January 2020 and December 2023, 25 patients with Child-Pugh B/C PVTT HCC were enrolled, and their overall survival with radiofrequency ablation treatment and the associated drivers were investigated. Results: Overall survival (median 282 days) differed between the group treated with transarterial chemoembolization (TACE, 285 days) and the group without it (159 days, p=0.0151). The median survival in the esophagogastric variceal exacerbation group (120.5 days) was shorter than that in the non-exacerbation group (284.0 days, p=0.00964). In multivariate analysis, concomitant TACE had a hazard ratio (HR) of 0.121 (p=0.0097), and the exacerbation of esophagogastric varices had a HR of 6.761 (p=0.01). Conclusion: Local ablation for PVTT may promote patient survival specifically by inhibiting the exacerbation of portal hypertension in patients with hepatocellular carcinoma.